American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therape

BACKGROUND The availability of more sensitive biomarkers of myonecrosis and a new classification system from the universal definition of myocardial infarction (MI) have led to evolution of the classification of MI. The prognostic implications of MI defined in the current era have not been well described. METHODS AND RESULTS We investigated the association between new or recurrent MI by subtype according to the European Society of Cardiology/American College of Cardiology/American Heart Association/World Health Federation Task Force for the Redefinition of MI Classification System and the risk of cardiovascular death among 13 608 patients with acute coronary syndrome in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). The adjusted risk of cardiovascular death was evaluated by landmark analysis starting at the time of the MI through 180 days after the event. Patients who experienced an MI during follow-up had a higher risk of cardiovascular death at 6 months than patients without an MI (6.5% versus 1.3%, P<0.001). This higher risk was present across all subtypes of MI, including type 4a (peri-percutaneous coronary intervention, 3.2%; P<0.001) and type 4b (stent thrombosis, 15.4%; P<0.001). After adjustment for important clinical covariates, the occurrence of any MI was associated with a 5-fold higher risk of death at 6 months (95% confidence interval 3.8-7.1), with similarly increased risk across subtypes. CONCLUSIONS MI is associated with a significantly increased risk of cardiovascular death, with a consistent relationship across all types as defined by the universal classification system. These findings underscore the clinical relevance of these events and the importance of therapies aimed at preventing MI.

[1]  S. Pocock,et al.  Prognostic Modeling of Individual Patient Risk and Mortality Impact of Ischemic and Hemorrhagic Complications: Assessment From the Acute Catheterization and Urgent Intervention Triage Strategy Trial , 2010, Circulation.

[2]  F. Werf Balancing benefit and bleeding risk of antithrombotic agents in the individual patient with an acute coronary syndrome. , 2010 .

[3]  A. Kastrati,et al.  Cangrelor - a champion lost in translation? , 2009, The New England journal of medicine.

[4]  E. Unger,et al.  Weighing benefits and risks--the FDA's review of prasugrel. , 2009, The New England journal of medicine.

[5]  Tobias Reichlin,et al.  Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. , 2009, The New England journal of medicine.

[6]  E. Antman,et al.  Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myo , 2009, American heart journal.

[7]  A. Jaffe,et al.  A translational approach to detecting drug-induced cardiac injury with cardiac troponins: consensus and recommendations from the Cardiac Troponins Biomarker Working Group of the Health and Environmental Sciences Institute. , 2009, American heart journal.

[8]  J. Alpert,et al.  Implications of the universal definition of myocardial infarction , 2008, Nature Clinical Practice Cardiovascular Medicine.

[9]  P. Jarolim,et al.  Implementation of a highly sensitive cardiac troponin I assay: test volumes, positivity rates and interpretation of results. , 2008, Clinica chimica acta; international journal of clinical chemistry.

[10]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[11]  D. Morrow,et al.  Earlier detection of myocardial injury in a preliminary evaluation using a new troponin I assay with improved sensitivity. , 2007, American journal of clinical pathology.

[12]  E. Antman,et al.  Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). , 2006, American heart journal.

[13]  M. Burritt,et al.  Baseline troponin level: key to understanding the importance of post-PCI troponin elevations. , 2006, European heart journal.

[14]  I. Porto,et al.  Impact of the elevation of biochemical markers of myocardial damage on long-term mortality after percutaneous coronary intervention: results of the CK-MB and PCI study. , 2005, European heart journal.

[15]  J. Ioannidis,et al.  Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. , 2003, Journal of the American College of Cardiology.

[16]  R. Bonow,et al.  Troponin I elevation and cardiac events after percutaneous coronary intervention. , 2003, American heart journal.

[17]  E. Topol,et al.  Frequency and long-term impact of myonecrosis after coronary stenting. , 2002, European heart journal.

[18]  E. Antman,et al.  The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. , 2000, JAMA.

[19]  R. Califf,et al.  Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. PURSUIT Steering Committee. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. , 2000, JAMA.

[20]  R. Califf,et al.  Acute Coronary Syndromes in the GUSTO-IIb Trial Prognostic Insights and Impact of Recurrent Ischemia , 1998 .

[21]  E. Topol,et al.  Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. , 1996, Circulation.

[22]  A. Ibrahim,et al.  Acute myocardial infarction. , 2014, Critical care clinics.

[23]  Anders Hamsten,et al.  70 – Atherosclerosis, Thrombosis, and Vascular Biology , 2012 .

[24]  J. Alpert,et al.  Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction , 2008 .

[25]  D. Ardissino,et al.  Impact of the elevation of biochemical markers of myocardial damage on long-term mortality after percutaneous coronary intervention: results of the CK-MB and PCI study. , 2005, European heart journal.

[26]  Samin K. Sharma,et al.  Correlation of postpercutaneous coronary intervention creatine kinase-MB and troponin I elevation in predicting mid-term mortality. , 2004, The American journal of cardiology.